Background
MK-677 (ibutamoren) is an orally bioavailable, non-peptide GH secretagogue that activates the ghrelin receptor (GHSR-1a), stimulating pulsatile growth hormone release from the anterior pituitary and downstream IGF-1 production. Unlike injectable peptide secretagogues (ipamorelin, GHRP-2, sermorelin), MK-677 achieves therapeutic GH axis stimulation via oral administration — making it a pharmacokinetically distinct but mechanistically equivalent approach to peptide GH secretagogues.
Svensson and colleagues at Sahlgrenska University Hospital evaluated the 2-month metabolic and body composition effects of MK-677 in obese adult males, a population with characteristically blunted GH secretion (obesity-related GH suppression due to elevated free fatty acids and insulin resistance), to establish whether GH secretagogue treatment could restore both GH axis function and drive anabolic body composition changes despite the suppressive metabolic milieu.
Methods
Design: Randomized, double-blind, placebo-controlled crossover trial
Population: 24 obese males (BMI 30–40 kg/m²), mean age 42 years, with low-normal fasting IGF-1
Treatment: MK-677 25 mg orally once daily for 2 months, followed by crossover to placebo (or vice versa) with 5-week washout period
Assessments: 24-hour GH sampling, serum IGF-1, body composition (DEXA), resting energy expenditure (indirect calorimetry), fasting glucose and insulin
Key Findings
GH Axis Activation:
- 24-hour mean GH concentration increased approximately 5-fold over baseline during MK-677 treatment
- IGF-1 rose from ~110 ng/mL to ~167 ng/mL (mean +52%, p < 0.01 vs. placebo)
- GH pulse amplitude increased without loss of pulsatility — secretagogue mechanism augments endogenous pulses rather than creating tonic suppression
- Persistent elevation maintained at end of 2-month treatment period
Body Composition (2-Month Treatment vs. Placebo):
| Parameter | MK-677 | Placebo | Difference |
|---|---|---|---|
| Fat-free mass change | +1.7 kg | −0.1 kg | +1.8 kg (p < 0.05) |
| Fat mass change | −0.4 kg | +0.3 kg | −0.7 kg (NS) |
| Body weight change | +1.3 kg | +0.2 kg | +1.1 kg (NS) |
| Waist circumference | −1.6 cm | +0.4 cm | −2.0 cm (p = 0.06) |
- Fat-free mass gain of 1.7 kg is clinically meaningful over a 2-month window, particularly in obese patients with baseline GH suppression
- Fat mass trend downward but 2-month duration insufficient for statistical significance; longer treatment anticipated to produce significant fat loss
- Net weight gain reflects the lean mass accrual — body composition shifted toward muscle despite scale weight change
Metabolic Effects:
| Parameter | MK-677 | Placebo | Change |
|---|---|---|---|
| Basal metabolic rate | +9% | −1% | +10% (p < 0.05) |
| Fasting glucose | +0.3 mmol/L | −0.1 mmol/L | NS |
| Fasting insulin | +22% | +4% | p = 0.09 (trend) |
- BMR increase of 9% attributed to lean tissue metabolic demand — sustained lean mass gain inherently increases resting caloric expenditure
- Mild insulin resistance trend consistent with known GH anti-insulin effect; not clinically significant at 2-month timepoint in otherwise healthy obese males
- No new-onset diabetes or clinically significant hyperglycemia
Adverse Effects:
- Increased appetite in 71% of MK-677 subjects — attributable to ghrelin receptor agonism (ghrelin is an orexigenic signal)
- Mild ankle edema in 4/24 subjects — transient, first 2 weeks only; resolved without dose change
- No serious adverse events
MK-677 Mechanism Advantage
Unlike peptide GH secretagogues that require subcutaneous injection and have short half-lives:
- MK-677 is orally bioavailable (single daily dose)
- Half-life: ~24 hours, supporting once-daily dosing
- Sustained 24-hour IGF-1 elevation rather than pulse-only stimulation
These pharmacokinetic differences mean MK-677 provides more continuous GH/IGF-1 axis stimulation compared to short-acting injected secretagogues (ipamorelin, GHRP-2), with body composition effects emerging from sustained rather than pulsatile anabolic signaling.
Clinical Significance
- Oral route for GH axis restoration: MK-677 provides a needle-free alternative for GH secretagogue therapy, with body composition effects consistent with injectable peptide secretagogues via the shared GHSR-1a mechanism
- Obese-specific benefit: GH suppression in obesity is a recognized contributor to sarcopenic obesity (simultaneous fat gain and muscle loss); secretagogue-driven restoration addresses both arms of this phenotype
- BMR therapeutic target: The 9% metabolic rate increase creates a secondary weight management benefit — each kg of lean mass adds ~13 kcal/day of resting expenditure
- 2-month proof-of-concept: The study establishes that even short-duration MK-677 treatment produces measurable body composition shifts, supporting the plausibility of greater effects with longer treatment courses
Limitations
- 2-month duration captures early body composition changes; maximal lean mass accrual from GH secretagogue therapy is expected to require 6–12 months
- Fat mass reduction not statistically significant at 2 months — anti-adiposity effects of GH restoration emerge more slowly than lean mass gains
- Obese male cohort only; GH secretagogue responses differ in females (higher baseline GH secretion), lean adults, and elderly populations with somatopause-related GH decline
- Increased appetite from ghrelin receptor agonism may partially offset fat loss — MK-677’s ghrelin axis effects are broader than selective peptide secretagogues
- No dietary or exercise standardization — nutrition and activity variations could confound body composition outcomes in free-living subjects